Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7994536 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL27586618 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL251323 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL519182 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL7072490 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL519027 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL251871 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL438865 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL251249 | 0.96 | ALDH1A1 (0.42) | ALDH1A1CNR1CNR2FAAHTRPV1 | |
| SCHEMBL250711 | 0.93 | ALDH1A1 (0.39) | ALDH1A1CNR1CNR2FAAHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075500-A | Capacitor with improved capacitance | 基美电子公司 | 2023-05-05 | — | — | CN | claimed |
| WO-2022035534-A2 | CAPACITORS WITH IMPROVED CAPACITANCE | KEMET ELECTRONICS CORPORATION (US) | 2022-02-17 | — | — | WO | claimed |
| US-20200373089-A1 | Capacitors with Improved Capacitance | KEMET ELECTRONICS CORPORATION | 2020-11-26 | — | — | US | claimed |
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2019-08-15 | — | — | US | claimed |
| CN-108401417-A | Including improving the cosmetics of nano-particle and preparation method thereof of active principle containing whitening | 郑汉洙 | 2018-08-14 | — | — | CN | claimed |
| US-20170224768-A1 | LEUKOTOXIN E/D AS A NEW ANTI-INFLAMMATORY AGENT AND MICROBICIDE | UNIV NEW YORK (US) | 2017-08-10 | — | — | US | claimed |
| US-9682068-B2 | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders | MYLAN INC. (US) | 2017-06-20 | — | — | US | claimed |
| EP-2294173-B1 | SURFACTANT GAS PRESSURIZED LIQUID COMPOSITION AND METHOD AND PACKAGE FOR DELIVERING | KIMBERLY CLARK CO (US) | 2017-04-26 | — | — | EP | claimed |
| CN-105722972-A | Cellular factors involved in the cytotoxicity of leukocidins of staphylococcus aureus: novel therapeutic target | 纽约大学 | 2016-06-29 | — | — | CN | claimed |
| US-20160168233-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | NEW YORK UNIVERSITY | 2016-06-16 | — | — | US | claimed |
| CN-1225575-A | Method for althering hair growth and hair pigmentation and compositions therefor | JOHNSON & JOHNSON CONSUMER (US) | 1999-08-11 | — | — | CN | claimed |
| WO-1999004752-A9 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998048775-A9 | SERINE PROTEASE AND TOPICAL RETINOID COMPOSITIONS | — | 1999-03-04 | — | — | WO | claimed |
| WO-1999004752-A2 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| WO-1998048775-A1 | SERINE PROTEASE AND TOPICAL RETINOID COMPOSITIONS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 1998-11-05 | — | — | WO | claimed |
| WO-1998046208-A1 | HAIR FOLLICLE DNA DELIVERY SYSTEM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-10-22 | — | — | WO | claimed |
| US-5720948-A | COMPRISING OIL, WATER, EMULSIFIER OF GLYCEROL DILAURATE AND POLYOXYETHYLENE-10 STEARYL ETHER | HELENE CURTIS INC. (US) | 1998-02-24 | — | — | US | claimed |
| WO-1998002134-A1 | METHODS FOR ALTERING HAIR GROWTH AND HAIR PIGMENTATION BY APOPTOSIS IN THE FOLLICULAR PAPILLAE AND COMPOSITIONS THEREFOR | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 1998-01-22 | — | — | WO | claimed |
| US-5672340-A | GEL OR SOLID; INCLUDES A BORATE CROSSLINKER, A NONIONIC SURFACTANT, WATER, AND A HYDROPHOBIC COMPOUND | HELENE CURTIS, INC. (US) | 1997-09-30 | — | — | US | claimed |
| EP-0676193-A2 | Topically effective compositions | HELENE CURTIS, INC. (US) | 1995-10-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | ALDH1A1 3600/4885CNR1 1739/4885CNR2 2896/4885 |
| US-20160168233-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | ALDH1A1 3600/4885CNR1 1739/4885CNR2 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.